UCB Group Release: New Post-Hoc Analyses Examined Neupro® Effects on Pain, Depressed Mood, Apathy and Fatigue in Patients with Parkinson’s Disease

ATLANTA--(BUSINESS WIRE)--Insights into the effects of Neupro® (rotigotine transdermal system) on common non-motor symptoms of Parkinson’s disease (PD) were presented today at the 64th AAN Annual Meeting in New Orleans, LA.